BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Replicate Bioscience Partners With Instituto Butantan To Advance Next Generation srRNA Rabies Vaccine Across Latin America

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunol...

December 05, 2025 | News

Neurimmune And Alexion Expand Global Collaboration To Advance NI009 For Light Chain Amyloidosis

Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease ...

December 05, 2025 | News

Kelun Biotech And Crescent Biopharma Forge Global Partnership To Advance Next Generation Oncology Therapies

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets an...

December 05, 2025 | News

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Aurigene Oncology Reports Strong Early Phase One Results For AUR112 In Relapsed And Refractory Lymphomas

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, announced initial clinical results...

December 04, 2025 | News

AdvanCell Launches Theraphase Two Expansion To Optimise Dosing For ADVC001 Across Key Prostate Cancer Settings

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will ...

December 04, 2025 | News

Antengene Secures NMPA Approval for IND of CLINCH Two Combination Study in Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

December 03, 2025 | News

NADMED Launches Global Award to Unlock the Secrets of Cellular Redox Metabolism

As scientists seek to understand the molecular basis of energy production, aging, and disease, one area remains especially elusive: cellular redox metaboli...

December 03, 2025 | News

IDEAYA Moves IDE034 Into Clinic Following FDA Clearance and Strong B7H3 PTK7 Co Expression

B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, r...

December 02, 2025 | News

Ascletis Advances First Oral Triple Agonist for Obesity, ASC37, into Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability ...

December 01, 2025 | News

Sanyou Bio Partners With FatiAbGen to Strengthen Korean Market Presence and Expand Global Biopharma Reach

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and South Korea's FatiAbGen Co., Ltd. jointly announced the signing of a...

November 28, 2025 | News

HKeyBio Expands Its Autoimmune and Allergy R&D Capabilities With HKEY-AIDMD 3.0 Platform Upgrade

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBi...

November 28, 2025 | News

Zydus and RK Pharma Partner on Innovative Sterile Injectable for Oncology Supportive Care

Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that it has entered into an e...

November 27, 2025 | News

Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

November 26, 2025 | News

Stay Connected